A Study of Methylprednisolone in People Having Liver Surgery
The purpose of this study is to test whether receiving methylprednisolone before surgery will reduce the side effects of having surgery, such as infections and longer hospital stays.
| Condition(s) | Hepatectomy |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Summary | The purpose of this study is to test whether receiving methylprednisolone before surgery will reduce the side effects of having surgery, such as infections and longer hospital stays. |
| Who can participate | Inclusion Criteria: * Age ≥18 years at the time of consent. * Scheduled to undergo elective major hepatectomy (defined by CPT codes 47122 \[trisegmentectomy\], 47125 \[total left hepatectomy\], or 47130 \[total right hepatectomy\]). * In addition to major hepatectomy, as defined above, patients may undergo additional partial hepatectomy or operative ablation. Exclusion Criteria: * Known or documented adverse reactions to methylprednisolone. * Unable to receive methylprednisolone because of coexisting medical conditions. * Long-term (≥10-day course) systemic corticosteroid use, regardless of dose, if doses have been administered within 30 days of the planned date of surgery. This will not apply to steroids administered, in accordance with the standard of care, with preoperative chemotherapy |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
| Locations | Chicago, Illinois, United States; Chicago, Illinois, United States; Indianapolis, Indiana, United States; Iowa City, Iowa, United States; Lexington, Kentucky, United States; Detroit, Michigan, United States (+13 more sites) |
| Start date | 2026-03-27 |
| NCT ID | NCT07507643 |
| Official listing | https://clinicaltrials.gov/study/NCT07507643 |